申请人:ISF SOCIETA PER AZIONI
公开号:EP0206729A2
公开(公告)日:1986-12-30
Compounds of Structure (1)
in which
R1 is H, Cl-5 alkyl (straight or branched), or a phenyl or benzyl group optionally substituted by C1-5 alkyl (straight or branched), C1-4 alkoxy (straight or branched) or hydroxy;
R2 is H, OH, Cl-5 alkyl (straight or branched), aryl or acyl;
R3 is H, C1-5 alkyl (straight or branched) or phenyl and R4 is Cl-5 alkyl (straight or branched) or phenyl, or R3 and R4 can together form a 1,4-butylene or 1,5-pentylene group;
R5 is H or C1-5 alkyl (straight or branched);
R6 is H, C1-5 alkyl (straight or branched), -CHR8CONH2 or -CHR8CONHCHR9CONH2; where R8 and R9 (which can be the same or different) are H or C1-5 alkyl (straight or branched); and
R7 is H or Cl-5 alkyl (straight or branched), and pharmaceutically acceptable salts thereof, processes and intermediates for making them, pharmaceutical compositions containing them and their use as nootropic agents.
结构 (1) 的化合物
其中
R1 是 H、Cl-5 烷基(直链或支链)或任选被 C1-5 烷基(直链或支链)、C1-4 烷氧基(直链或支链)或羟基取代的苯基或苄基;
R2 是 H、OH、Cl-5 烷基(直链或支链)、芳基或酰基;
R3 是 H、C1-5 烷基(直链或支链)或苯基,R4 是 Cl-5 烷基(直链或支链)或苯基,或 R3 和 R4 可共同形成 1,4-丁烯或 1,5-戊烯基团;
R5 是 H 或 C1-5 烷基(直链或支链);
R6 是 H、C1-5 烷基(直链或支链)、-CHR8CONH2 或 -CHR8CONHCHR9CONH2;其中 R8 和 R9(可以相同或不同)是 H 或 C1-5 烷基(直链或支链);以及
R7是H或Cl-5烷基(直链或支链),以及它们的药学上可接受的盐、制造它们的工艺和中间体、含有它们的药物组合物和它们作为促智剂的用途。